Peter Schmid News Today

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

PUMA's sneaker archive is filled with left-field shoes that are starting to get the attention they deserve. We deep-dived into some of its most wild sneakers.

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

Biometrics and digital ID security companies in the U.S. and Germany have announced the appointment of new members to advisory roles.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer.

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer. 

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.

In the picturesque Black Hills region Peter Schmid is capitalizing on a lucrative trend in the housing market by offering short-term rentals in Rapid City.